Yifat Vanepp

Q: What is Yifat Van Epp email address?

Email Yifat Van Epp at yig10@yahoo.com and yvanepp@its.jnj.com. This email is the most updated Yifat Van Epp's email found in 2026.

Q: How to contact Yifat Van Epp?

To contact Yifat Van Epp send an email to yig10@yahoo.com or yvanepp@its.jnj.com. (updated on June 28, 2025)

Senior Medical Science Liaison at The Janssen Pharmaceutical Companies of Johnson & Johnson | Scottsdale, Arizona, United States

About Yifat Vanepp

Yifat Van Epp currently serves as the Interim Field Director for Myeloma and CAR-T Medical Science Liaisons (MSLs) at The Janssen Pharmaceutical Companies of Johnson & Johnson, where she leverages her extensive expertise in hematology, oncology, and translational research to drive strategic field initiatives. In this pivotal role, Yifat oversees a team of highly skilled MSLs dedicated to advancing the understanding and adoption of innovative therapies such as CAR-T cell treatments for multiple myeloma, ensuring alignment with clinical development and real-world evidence generation. Her leadership is instrumental in fostering strong relationships with key investigators, healthcare professionals, and research institutions, facilitating collaborative clinical research projects, and supporting the successful launch and ongoing education of groundbreaking oncology products.

Yifat’s background in launching high-profile therapies like Erleada® for prostate cancer and Yondelis® for soft tissue sarcomas underscores her proficiency in product commercialization, clinical trial management, and strategic stakeholder engagement. Her expertise in managing complex translational research projects, coupled with her skills in biomarkers, pharmacology, and mass spectrometry, enables her to bridge the gap between laboratory discoveries and clinical applications effectively. As a former National Oncology MSL Lead and US Compound MSL Lead, she has demonstrated exceptional leadership in clinical research collaborations, investigator-initiated studies, and cross-sector relationship management. Her role as Editor & Chief of the Prostate Cancer journal further highlights her commitment to advancing scientific knowledge and thought leadership within the oncology community. Overall, Yifat’s multifaceted expertise and strategic vision continue to contribute significantly to Janssen’s mission of transforming patient outcomes through innovative hematology and oncology therapies.

Yifat Vanepp Work